Mesoblast Limited in brief
Mesoblast Limited is a listed company in the Biotechnology industry, based in Australia. Its last known market value was $169 M (January 2024); there is no current figure. In the year to June 2025 it had sales of $17 M and a net loss of $102 M. Its largest product and service lines by sales in 2026 were Ryoncil (96%). Its shares trade under the symbol MSB.AX (ASX).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Mesoblast Limited
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Mesoblast Limited timeline
- 2004
- 📈Listed on Australian Securities Exchange as MSB
Events of Mesoblast Limited from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Australia: #180 (Jan 2020) · #176 (Jan 2021) · #277 (Jan 2022) · #264 (Dec 2022) · #229 (Jul 2023) · #399 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -593.8%
- Operating margin
- —
- Return on equity
- -17.1%
- Liabilities / assets
- 23.9%
- Net debt
- $-94M
- Revenue growth
- +191.5%
- R&D / revenue
- 202.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2025 | $17M | +191.5% | — | $-102M | -593.8% |
| Jun 2024 | $6M | -21.3% | — | $-88M | -1490.8% |
| Jun 2023 | $8M | -26.5% | — | $-82M | -1091.9% |
| Jun 2022 | $10M | +37.4% | — | $-91M | -894.7% |
| Jun 2021 | $7M | -76.9% | — | $-99M | -1329.9% |
| Jun 2020 | $32M | +92.3% | — | $-78M | -242.4% |
| Jun 2019 | $17M | -3.6% | — | $-90M | -537.1% |
| Jun 2018 | $17M | — | — | $-35M | -203.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2025 | $-50M | $1M | $-51M | $-0.08 | — |
| Jun 2024 | $-48M | $0M | $-49M | $-0.09 | — |
| Jun 2023 | $-63M | $0M | $-64M | $-0.11 | — |
| Jun 2022 | $-66M | — | — | $-0.13 | — |
| Jun 2021 | $-101M | — | — | $-0.16 | — |
| Jun 2020 | $-50M | — | — | $-0.15 | — |
| Jun 2019 | $-58M | — | — | $-0.18 | — |
| Jun 2018 | $-75M | — | — | $-0.08 | — |
SEC filings
- Nov 12, 20266-KReport of foreign issuer
- Nov 3, 20266-KReport of foreign issuer
- Oct 29, 20266-KReport of foreign issuer
- Oct 16, 20266-KReport of foreign issuer
- Oct 15, 20266-KReport of foreign issuer
- Oct 13, 20266-KReport of foreign issuer
- Sep 24, 20266-KReport of foreign issuer
- Aug 27, 20266-KReport of foreign issuer
- Aug 27, 202620-FAnnual report (foreign issuer) · period to Jun 2026
- Aug 25, 20266-KReport of foreign issuer
- Aug 24, 20266-KReport of foreign issuer
- Aug 18, 20266-KReport of foreign issuer
Official filings of Mesoblast Limited with the US Securities and Exchange Commission.
Annual results
- Revenue
- $17 M
- Operating income
- —
- Net income
- $-102 M
For year ending June-2025 · source: SEC filing
Balance sheet
- Total assets
- $785 M
- Total liabilities
- $187 M
- Total equity
- $597 M
As of June-2025
Mutual funds holding Mesoblast Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc. | 12.01 M | $17 M | — | <0.01% | −12% | Jul 31, 2026 |
| 🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc. | 8.01 M | $11 M | — | <0.01% | −11% | Jun 30, 2026 |
| 🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors | 6.88 M | $10 M | — | <0.01% | +1.2% | Jul 31, 2026 |
| 🇺🇸 The Asia Pacific Small Company SeriesDimensional Fund Advisors LP | 4.45 M | $6 M | — | 0.37% | −5.0% | Jul 31, 2026 |
| 🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc. | 3.11 M | $4 M | — | 0.03% | −11% | Jul 31, 2026 |
| 🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors | 3.07 M | $4 M | — | 0.03% | −15% | Jul 31, 2026 |
| 🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc. | 1.99 M | $3 M | — | 0.05% | +2.3% | May 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 1.26 M | $2 M | — | 0.03% | −8.6% | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI International Developed Markets ETFBlackRock Fund Advisors | 1.23 M | $2 M | — | <0.01% | +4.7% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc. | 1.18 M | $2 M | — | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 1.05 M | $2 M | — | <0.01% | +2.9% | Jul 31, 2026 |
| 🇺🇸 Vanguard Pacific Stock Index FundThe Vanguard Group, Inc. | 878,924 | $1 M | — | <0.01% | −13% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 775,076 | $1 M | — | <0.01% | +0.8% | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI Total International Stock ETFBlackRock Fund Advisors | 749,779 | $1 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 701,866 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 598,611 | $1 M | — | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC | 489,428 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB | 503,943 | $1 M | — | 0.02% | +27% | Jun 30, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 399,292 | $1 M | — | <0.01% | −3.9% | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 378,277 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 379,344 | $1 M | — | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc. | 279,136 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Core MSCI Pacific ETFBlackRock Fund Advisors | 245,596 | $0 M | — | 0.01% | +3.3% | Jul 31, 2026 |
| 🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC | 236,720 | $0 M | — | 0.03% | −8.6% | Jul 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 200,912 | $0 M | — | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 173,604 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Innovate Equity ETFGoldman Sachs Asset Management, L.P. | 101,936 | $0 M | — | 0.07% | −3.5% | May 31, 2026 |
| 🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust | 100,665 | $0 M | — | 0.05% | +19% | May 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 106,728 | $0 M | — | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP | 103,674 | $0 M | — | <0.01% | −22% | Jul 31, 2026 |
| 🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP | 98,564 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 79,233 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors | 48,709 | $0 M | — | 0.01% | −28% | May 31, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 37,977 | $0 M | — | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional International Sustainability Core 1 ETFDimensional Fund Advisors LP | 35,588 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 37,595 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc. | 29,959 | $0 M | — | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 FlexShares Morningstar Developed Markets ex-US Factor Tilt Index FundNorthern Trust Investments, Inc. | 22,320 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC | 8,774 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Mesoblast Limited#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +2.32 M | 1.480 | 3.4 Mlocal | 8.32 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +2.32 M | 1.480 | 3.4 Mlocal | 8.32 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +886,890 | 1.430 | 1.3 Mlocal | 12.89 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +105,000 | 1.460 | 153 Klocal | 12.99 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +500,000 | 1.440 | 720 Klocal | 13.49 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +10,000 | 1.440 | 14 Klocal | 13.50 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +4,760 | 1.440 | 7 Klocal | 13.51 M | Form 4 |
| filed | Gregory GeorgeDirector, 10% owner | Buyindirect | +20,000 | 1.430 | 29 Klocal | 13.53 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: Mesoblast Limited#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 4,216 shares at $15.67
- : 213 shares at $13.39
- : 119 shares at $13.18
- : 1,108 shares at $12.39
- : 1,793 shares at $12.28
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Mesoblast Limited scorecard#
Passes 6 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in profitability (0 of 3). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth3 of 6
- ✓Revenue grew in the newest year191.5%Revenue up 191.5% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years19.0%19.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median19.0%19.0% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.08 vs -0.09Diluted EPS -0.08 in fiscal 2025 against -0.09 the year before (report's currency).
- ✗Net income higher than five years earlier-$102 M-$102 M in fiscal 2025 against -$78 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$102 MNet income -$102 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-18.9%-18.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 4
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.99 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $94 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year22.4%Diluted shares up 22.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Mesoblast Limited's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Net margin | -593.8% | -68.9% | |
| Return on equity | -19.0% | -61.0% | |
| Revenue growth, 3 years a year | 19.0% | 12.9% | |
| Revenue growth | 191.5% | 15.8% | |
| Debt to equity | 0.11× | 0.26× | |
| Free cash flow margin | -294.4% | -61.5% |
5of 9on the Piotroski tests of financial strength
- Net loss of $102 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$51 million.
- The share count rose 22.4% in the year.
- More cash than debt: net cash of $94 million.
Mesoblast Limited: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 | FY 2016to Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 17+191%100% | 5.9−21.3%100% | 7.5−26.5%100% | 10r10+37.4%100% | 7.4r7.5−76.9%100% | 32+92.3%100% | 17−3.6%100% | 17+619%100% | 2.4−94.3%100% | 43—100% | |
| Cost of revenue | 5.1—29.8% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Research and development | 35−12.4%202% | 40r25−24.8%673% | 53r27+61.0%704% | 33−38.1%321% | 53−5.7%713% | 56−6.1%175% | 60−9.3%358% | 66+11.9%380% | 59+17.8%2443% | 50—118% | |
| Selling, general and administrative | 39+57.4%229% | 25−9.1%423% | 27—366% | — | — | — | — | — | — | — | |
| Interest and finance income | 3.6+94.8%20.7% | 1.8+119%30.9% | 0.8+27600%11.1% | 0.0−86.4%0.0% | 0.0−95.9%0.3% | 0.5−24.6%1.7% | 0.7+96.4%4.3% | 0.4−21.8%2.1% | 0.5−56.6%19.4% | 1.1—2.5% | |
| Interest expense and finance costs | 23−0.2%134% | 23+14.3%390% | 20+16.4%268% | 17+61.4%169% | 11−24.1%144% | 14r13+16.8%43.9% | 12r11+560%72.2% | 1.8—10.5% | — | — | |
| Income before tax | −102—−592% | −88—−1494% | −82—−1095% | −92—−897% | −100—−1340% | −87—−272% | −99—−591% | −66—−380% | −90—−3740% | −91—−213% | |
| Income tax | 0.3—1.9% | −0.2—−3.2% | −0.2—−2.8% | −0.2—−2.3% | −0.8—−11.0% | −9.4—−29.3% | −9.0—−53.6% | −31—−177% | −13—−556% | −87—−204% | |
| Net income including minority interests | −102—−594% | −88—−1490% | −82—−1092% | −91—−895% | −99—−1329% | −78—−242% | −90—−537% | −35—−204% | −77—−3185% | −4.1—−9.7% | |
| Net income attributable to shareholders | −102—−594% | −88—−1490% | −82—−1092% | −91—−895% | −99—−1329% | −78—−242% | −90—−537% | −35—−204% | −77—−3185% | −4.1—−9.7% | |
| Earnings per share, basic | -0.08—— | -0.09—— | -0.11r-0.11—— | -0.13r-0.14—— | -0.16—— | -0.15—— | -0.18—— | -0.08—— | -0.19—— | -0.01—— | |
| Earnings per share, diluted | -0.08—— | -0.09—— | -0.11r-0.11—— | -0.13r-0.14—— | -0.16—— | -0.15—— | -0.18—— | -0.08—— | -0.19—— | -0.01—— | |
| Shares, weighted average (basic) | 1,208+22.4%— | 987+26.9%— | 778r739+13.9%— | 683r649+12.9%— | 605+14.4%— | 529+7.0%— | 494+6.2%— | 466+16.7%— | 399+9.6%— | 364—— | |
| Shares, weighted average (diluted) | 1,208+22.4%— | 987+26.9%— | 778r739+13.9%— | 683r649+12.9%— | 605+14.4%— | 529+7.0%— | 494+6.2%— | 466+16.7%— | 399+9.6%— | 364—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 162+157%20.6% | 63−11.7%9.4% | 71+18.0%10.7% | 60−55.8%9.1% | 137+5.8%18.4% | 129+156%17.6% | 50+33.5%7.7% | 38−17.5%5.5% | 46−43.5%7.0% | 81—— | |
| Receivables | 15−29.0%1.9% | 21+199%3.1% | 7.0+58.9%1.0% | 4.4−9.1%0.7% | 4.8+208%0.7% | 1.6−61.2%0.2% | 4.1−91.9%0.6% | 50+1246%7.3% | 3.7—0.6% | — | |
| Inventory | 22—2.8% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Current assets | 204+136%26.0% | 86+5.9%12.9% | 82+16.9%12.2% | 70−52.9%10.5% | 148+8.6%19.9% | 137+118%18.6% | 63−38.1%9.6% | 101+58.9%14.6% | 64—9.7% | — | |
| Property, plant and equipment | 1.7+53.9%0.2% | 1.1−18.5%0.2% | 1.4−33.6%0.2% | 2.0−32.3%0.3% | 3.0+31.7%0.4% | 2.3+178%0.3% | 0.8−23.8%0.1% | 1.1−40.2%0.2% | 1.8−40.8%0.3% | 3.1—— | |
| Right-of-use (leased) assets | 4.1+50.8%0.5% | 2.7−46.8%0.4% | 5.1−35.2%0.8% | 7.9−13.1%1.2% | 9.1+14.3%1.2% | 8.0—1.1% | — | — | — | — | |
| Non-current assets | 580−0.4%74.0% | 583−0.9%87.1% | 588−0.8%87.8% | 592−0.7%89.5% | 596−0.1%80.1% | 597+1.3%81.4% | 590−0.3%90.4% | 591−0.1%85.4% | 592—90.3% | — | |
| Total assets | 785+17.3%100% | 669−0.0%100% | 669+1.1%100% | 662−11.1%100% | 745+1.5%100% | 734+12.5%100% | 652−5.8%100% | 692+5.6%100% | 656—100% | — | |
| Accounts payable | 19+170%2.4% | 7.1−64.9%1.1% | 20−12.7%3.0% | 23+17.8%3.5% | 20−21.5%2.6% | 25+91.2%3.4% | 13−31.0%2.0% | 19−13.2%2.7% | 22—3.3% | — | |
| Current liabilities | 103+40.1%13.1% | 73+74.5%10.9% | 42−18.3%6.3% | 51−45.5%7.8% | 94+4.6%12.7% | 90+103%12.3% | 44+84.7%6.8% | 24−34.5%3.5% | 37—5.6% | — | |
| Long-term debt | 68−32.6%8.6% | 100−2.3%15.0% | 103+12.2%15.4% | 92+123%13.8% | 41−28.0%5.5% | 57−15.2%7.8% | 67+13.3%10.3% | 59—8.6% | — | — | |
| Lease liabilities (non-current) | 3.6+83.6%0.5% | 2.0−46.8%0.3% | 3.7−48.2%0.5% | 7.1−16.5%1.1% | 8.5+34.3%1.1% | 6.3—0.9% | — | — | — | — | |
| Non-current liabilities | 85−26.8%10.8% | 116−8.0%17.3% | 126+10.4%18.8% | 114+64.7%17.2% | 69−26.6%9.3% | 94−25.7%12.8% | 127+3.5%19.4% | 122+19.7%17.7% | 102—15.6% | — | |
| Total liabilities | 187−0.8%23.9% | 189+12.7%28.2% | 168+1.5%25.0% | 165+1.1%24.9% | 163−11.4%21.9% | 184+7.7%25.1% | 171+16.8%26.2% | 146+5.4%21.1% | 139—21.2% | — | |
| Retained earnings | −1,011—−129% | −909—−136% | −821—−123% | −739—−112% | −648—−87.0% | −549—−74.8% | −470—−72.1% | −380—−54.9% | −345—−52.6% | — | |
| Total equity | 597+24.4%76.1% | 480−4.3%71.8% | 502+1.0%75.0% | 497−14.5%75.1% | 581+5.8%78.1% | 549+14.2%74.9% | 481−11.9%73.8% | 546+5.7%78.9% | 517−2.2%78.8% | 528—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 6.4+37.2%37.2% | 4.7+13.6%79.1% | 4.1−6.2%54.8% | 4.4+2.7%42.9% | 4.3+16.3%57.4% | 3.7+71.4%11.4% | 2.1−19.3%12.8% | 2.7−13.3%15.3% | 3.1+39.5%127% | 2.2—5.2% | |
| Share-based compensation | 22+276%128% | 5.9+60.6%99.5% | 3.7−34.0%48.7% | 5.5−55.7%54.2% | 13+66.3%168% | 7.5+72.2%23.4% | 4.4−29.5%26.1% | 6.2+17.5%35.7% | 5.3+55.7%219% | 3.4—8.0% | |
| Cash from operating activities | −50—−290% | −48—−821% | −63—−843% | −66—−644% | −101r−107—−1355% | −50r−56—−157% | −58—−346% | −75—−433% | −95—−3958% | −88—−207% | |
| Capital expenditure | −0.7—−4.0% | −0.3—−4.6% | −0.3—−3.5% | — | — | — | — | — | — | — | |
| Intangible assets bought | −0.1—−0.3% | −0.1—−1.0% | −0.1—−0.7% | −0.1—−0.7% | 0—0.0% | −0.2—−0.5% | — | — | — | — | |
| Cash from investing activities | 0.1—0.7% | −0.1—−1.6% | −0.2—−2.6% | −0.2—−2.3% | −1.6—−22.2% | −3.3—−10.2% | −1.0—−6.0% | −1.2−912%−6.6% | 0.1—5.9% | −1.7—−4.1% | |
| Debt issued | — | 0—0.0% | 0−100%0.0% | 52—508% | 0−100%0.0% | 0.5−98.8%1.6% | 44+37.4%261% | 32—183% | — | — | |
| Debt repaid | −7.8—−45.5% | −10—−169% | 0—0.0% | −55—−543% | 0—0.0% | −0.5—−1.6% | — | — | — | — | |
| Shares issued | 161+146%937% | 65−26.2%1108% | 89+42309%1182% | 0.2−99.8%2.0% | 106−26.7%1429% | 145+379%451% | 30−25.4%181% | 41−34.5%234% | 62−9.7%2568% | 69—161% | |
| Cash from financing activities | 147+266%857% | 40−46.0%682% | 75—993% | −9.9−109%−96.7% | 109r114−17.2%1460% | 131r137+83.1%408% | 72+4.4%428% | 69+14.3%396% | 60−3.3%2488% | 62—146% | |
| Exchange-rate effect on cash | 1.1—6.3% | −0.1—−0.9% | −0.2—−2.2% | −0.6−139%−5.4% | 1.4−5.4%19.0% | 1.5—4.7% | −0.2—−0.9% | −0.4−401%−2.6% | 0.1—6.1% | −2.1—−5.0% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Mesoblast Limited sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Ryoncil$115 M96%+923%
Source: SEC annual report (XBRL data) · as of Jun 30, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $7 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Mesoblast Limited compares in Biotechnology
- Revenue$17 M · higher than 49% of 647
- Net margin-593.8% · higher than 10% of 408
- Revenue growth191.5% · higher than 89% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Mesoblast Limited🇦🇺 | $169 M | — | -593.8% | +191.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending June-2025
- Balance sheet:
- As of June-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, Wikipedia, Wikidata; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Mesoblast Limited? Verify and update this profile — free
Show Mesoblast Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.